PACB Pacific Biosciences Of California Inc

Price (delayed)

$25.46

Market cap

$5.07B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.33

Enterprise value

$5.54B

Pacific Biosciences of California, Inc. is empowering life scientists with highly accurate long-read sequencing. The company's innovative instruments are based on Single Molecule, Real-Time (SMRT®) Sequencing technology, which delivers a ...

Highlights
Pacific Biosciences Of California's gross profit has increased by 33% YoY and by 19% QoQ
The revenue has increased by 28% YoY and by 15% QoQ
PACB's net income has shrunk by 51% YoY and by 30% QoQ
The quick ratio has contracted by 26% from the previous quarter

Key stats

What are the main financial stats of PACB
Market
Shares outstanding
199M
Market cap
$5.07B
Enterprise value
$5.54B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
19.56
Price to sales (P/S)
47.77
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
52.37
Earnings
Revenue
$105.83M
EBIT
-$71.83M
EBITDA
-$62.38M
Free cash flow
-$73.46M
Per share
EPS
-$0.33
Free cash flow per share
-$0.37
Book value per share
$1.3
Revenue per share
$0.53
TBVPS
$6.27
Balance sheet
Total assets
$1.25B
Total liabilities
$987.54M
Debt
$935.84M
Equity
$258.25M
Working capital
$1.14B
Liquidity
Debt to equity
3.62
Current ratio
26.17
Quick ratio
25.63
Net debt/EBITDA
-7.63
Margins
EBITDA margin
-58.9%
Gross margin
42.7%
Net margin
-73%
Operating margin
-112.9%
Efficiency
Return on assets
-9.6%
Return on equity
-30.8%
Return on invested capital
-8.5%
Return on capital employed
-6%
Return on sales
-67.9%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

PACB stock price

How has the Pacific Biosciences Of California stock price performed over time
Intraday
-2.49%
1 week
-7.11%
1 month
-15.36%
1 year
165.21%
YTD
-1.85%
QTD
-27.19%

Financial performance

How have Pacific Biosciences Of California's revenue and profit performed over time
Revenue
$105.83M
Gross profit
$45.2M
Operating income
-$119.44M
Net income
-$77.21M
Gross margin
42.7%
Net margin
-73%
PACB's net income has shrunk by 51% YoY and by 30% QoQ
Pacific Biosciences Of California's gross profit has increased by 33% YoY and by 19% QoQ
The revenue has increased by 28% YoY and by 15% QoQ
The net margin is down by 18% year-on-year and by 14% since the previous quarter

Growth

What is Pacific Biosciences Of California's growth rate over time

Valuation

What is Pacific Biosciences Of California stock price valuation
P/E
N/A
P/B
19.56
P/S
47.77
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
52.37
The EPS has contracted by 22% from the previous quarter
The P/B is 97% above the 5-year quarterly average of 10.2 and 6% above the last 4 quarters average of 18.9
The company's equity fell by 8% QoQ
The revenue has increased by 28% YoY and by 15% QoQ
The price to sales (P/S) is 7% lower than the last 4 quarters average of 52.7

Efficiency

How efficient is Pacific Biosciences Of California business performance
The company's return on invested capital has surged by 82% YoY and by 34% QoQ
The ROE has soared by 69% YoY but it has contracted by 2.3% from the previous quarter
PACB's ROA has soared by 65% YoY and by 12% from the previous quarter
The ROS has contracted by 13% YoY and by 9% from the previous quarter

Dividends

What is PACB's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for PACB.

Financial health

How did Pacific Biosciences Of California financials performed over time
The company's total assets is 26% higher than its total liabilities
The company's current ratio fell by 26% QoQ
The quick ratio has contracted by 26% from the previous quarter
The company's equity fell by 8% QoQ
The company's debt to equity rose by 8% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.